Parunoflast vs Ruvonoflast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: NLRP3 inflammasome · full Obesity pipeline

Parunoflast

Developed by Eli Lilly and partners

Phase 2 in Obesitysmall molecule
Weak signal

NCT06771115 · Phase 2 · completed

Randomised, quadruple-blind, placebo-controlled Phase 2 (n=175) in obesity with cardiovascular risk factors. The primary endpoint was safety and tolerability, and it was met: adverse-event rates were similar to placebo. VTX3232 lowered hsCRP, but it did not reduce body weight alone or on top of semaglutide, so the study gives no evidence of efficacy on weight. Registry results were posted on 2026-09-29; the efficacy figures come from the sponsor's release. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion (Day 1 of treatment period through study completion, up to 16 weeks): Primary (safety): TEAE incidence placebo 49% vs VTX3232 46% (monotherapy arms); placebo+semaglutide 56% vs VTX3232+semaglutide 56%. Secondary: hsCRP -78% at week 12 with VTX3232 vs +3% with placebo (modified analysis set, p<0.0001). Weight: no weight loss with VTX3232 alone and no added weight loss over semaglutide (sponsor release). (met)

Result source: NCT06771115

Ruvonoflast

Developed by Rezera

Phase 2 in Obesitysmall molecule
Partial signal

NCT07055516 · Phase 2 · completed

The trial was randomized, triple-blind, placebo-controlled, and included 176 participants. Its primary outcomes included the surrogate biomarker hsCRP and change in body weight.

Reported efficacy

Ratio Change in hsCRP in participants with obesity and without T2DM hsCRP (Baseline to Week 24); Change in body weight in participants with obesity with and without T2DM (Baseline to Week 24): Primary endpoint met: change from baseline in hsCRP up to week 24; effect sizes not yet given (RESOLVE-1, 2026-09-09). (met)

Result source: NCT07055516

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointParunoflastRuvonoflast
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

Parunoflast
—Not reported
Ruvonoflast
—Not reported

Weight loss of 5% or more

Parunoflast
—Not reported
Ruvonoflast
—Not reported

Weight loss of 10% or more

Parunoflast
—Not reported
Ruvonoflast
—Not reported

Waist circumference, change (cm)

Parunoflast
—Not reported
Ruvonoflast
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Parunoflast: registry results are on file for Obesity, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ruvonoflast
Primary endpoint met: change from baseline in hsCRP up to week 24; effect sizes not yet given (RESOLVE-1, 2026-09-09). NCT07055516 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Phase Ib/IIa trial in 67 obese subjects with elevated CV risk/CRP, 28-day in-clinic dosing. >75% of NT-0796-dosed subjects reached hsCRP ≤2mg/L at day 28 vs <25% of placebo subjects; primary endpoint (hsCRP reduction) met with high statistical significance. NCT06129409 · Phase 1 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Parunoflast's landscape · Ruvonoflast's landscape